Bradley Saenger - 24 Feb 2026 Form 4 Insider Report for Tonix Pharmaceuticals Holding Corp. (TNXP)

Role
Chief Financial Officer
Signature
/s/ Bradley Saenger
Issuer symbol
TNXP
Transactions as of
24 Feb 2026
Net transactions value
$0
Form type
4
Filing time
26 Feb 2026, 07:03:05 UTC
Previous filing
17 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
SAENGER BRADLEY Chief Financial Officer C/O TONIX PHARMACEUTICALS HOLDING CORP, 200 CONNEL DRIVE, SUITE 3100, BERKLEY HEIGHTS /s/ Bradley Saenger 26 Feb 2026 0001668150

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TNXP Stock Option Award $0 +39,012 $0.000000 39,012 24 Feb 2026 Common Stock 39,012 $14.29 Direct F1, F2
transaction TNXP Stock Option Award $0 +39,011 $0.000000 39,011 24 Feb 2026 Common Stock 39,011 $17.86 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One-third of the option vests on the first anniversary of issuance and 1/48th each month thereafter for 36 months.
F2 The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended.